(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of 7.72% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 2.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.2%.
Astrazeneca's revenue in 2023 is $45,154,000,000.On average, 3 Wall Street analysts forecast AZN's revenue for 2023 to be $71,633,306,808,000, with the lowest AZN revenue forecast at $71,254,440,000,000, and the highest AZN revenue forecast at $72,152,280,000,000. On average, 3 Wall Street analysts forecast AZN's revenue for 2024 to be $78,363,902,448,000, with the lowest AZN revenue forecast at $75,339,658,440,000, and the highest AZN revenue forecast at $82,545,552,000,000.
In 2025, AZN is forecast to generate $88,053,336,000,000 in revenue, with the lowest revenue forecast at $84,076,524,000,000 and the highest revenue forecast at $92,030,148,000,000.